Last reviewed · How we verify
Trimetazidine hydrochloride
Trimetazidine hydrochloride is a metabolic modulator that improves cardiac efficiency by optimizing energy production in heart cells.
Trimetazidine hydrochloride is a metabolic modulator that improves cardiac efficiency by optimizing energy production in heart cells. Used for Angina pectoris, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Trimetazidine hydrochloride |
|---|---|
| Also known as | TH |
| Sponsor | The First Affiliated Hospital of Zhengzhou University |
| Drug class | Metabolic modulator |
| Target | 3-Ketoacyl CoA thiolase (3-KAT) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting long-chain 3-ketoacyl CoA thiolase (3-KAT), which is involved in the breakdown of fatty acids in the mitochondria. This leads to a reduction in the production of reactive oxygen species and an increase in the production of ATP, resulting in improved cardiac function.
Approved indications
- Angina pectoris
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients (PHASE3)
- Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Efficacy of Trimetazidine in Diabetic Patients (PHASE2)
- Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris (PHASE4)
- Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity (NA)
- Treatment of Intermediate-stage Hepatocellular Carcinoma (PHASE3)
- Treatment of Advanced Hepatocellular Carcinoma (PHASE3)
- Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: